IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-58431-z.html
   My bibliography  Save this article

Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy

Author

Listed:
  • Zhixiang Chen

    (University of Michigan
    Chinese Academy of Sciences)

  • Harshil Dhruv

    (SK Life Sciences Labs)

  • Xuqing Zhang

    (SK Life Sciences Labs)

  • Rohan Kalyan Rej

    (University of Michigan)

  • Longchuan Bai

    (University of Michigan)

  • Donna McEachern

    (University of Michigan)

  • Paul Kirchhoff

    (University of Michigan)

  • Rakesh Nagilla

    (SK Life Sciences Labs)

  • Larry J. Jolivette

    (SK Life Sciences Labs)

  • Cory T. Rice

    (SK Life Sciences Labs)

  • Peter Orth

    (SK Life Sciences Labs)

  • Corey O. Strickland

    (SK Life Sciences Labs)

  • E. Scott Priestley

    (SK Life Sciences Labs)

  • Helai P. Mohammad

    (SK Life Sciences Labs)

  • Meilin Wang

    (University of Michigan)

  • Bo Wen

    (University of Michigan)

  • Duxin Sun

    (University of Michigan)

  • Zhihua Sui

    (SK Life Sciences Labs)

  • Shaomeng Wang

    (University of Michigan)

Abstract

IKZF2 (Helios) is a transcription factor that is selectively expressed by Tregs and is essential for preserving the function and stability of Tregs in the tumor microenvironment (TME), where it suppresses the anti-tumor immune response. Targeted IKZF2 degradation by small molecules represents a promising strategy for the development of a new class of cancer immunotherapy. Herein, we describe the discovery of PVTX-405, a potent, effective, highly selective, and orally efficacious IKZF2 molecular glue degrader. PVTX-405 degrades IKZF2 (DC50 = 0.7 nM and Dmax = 91%) while sparing other CRBN neo-substrates. Degradation of IKZF2 by PVTX-405 increases production of inflammatory cytokine IL-2 and reduces the suppressive activity of Tregs, leading to an increase in Teff cell proliferation. Once-daily oral administration of PVTX-405 as single agent significantly delays the growth of MC38 tumors in a syngeneic tumor model using humanized CRBN mice. PVTX-405 in combination with anti-PD1 or anti-LAG3 significantly increases animal survival compared to anti-PD1 or anti-LAG3 alone. Together, these results demonstrate that PVTX-405 is a promising IKZF2 degrader for clinical development for the treatment of human cancers.

Suggested Citation

  • Zhixiang Chen & Harshil Dhruv & Xuqing Zhang & Rohan Kalyan Rej & Longchuan Bai & Donna McEachern & Paul Kirchhoff & Rakesh Nagilla & Larry J. Jolivette & Cory T. Rice & Peter Orth & Corey O. Strickla, 2025. "Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy," Nature Communications, Nature, vol. 16(1), pages 1-16, December.
  • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58431-z
    DOI: 10.1038/s41467-025-58431-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-58431-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-025-58431-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58431-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.